Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2002 Nov 26;167(11):1261-6.

Common problems in the management of hypertriglyceridemia

Michelle A Fung  1 , Jiri J Frohlich
Affiliations
Case Reports

Common problems in the management of hypertriglyceridemia

Michelle A Fung et al. CMAJ. .

Erratum in

  • CMAJ. 2003 Jan 7;168(1):16.
No abstract available

PubMed Disclaimer

Figures

None
Fig. 1: Triglyceride pathway. The gut produces chylomicrons following the absorption of fat. The triglyceride (TG) component of chylomicrons is removed by lipoprotein lipase located on the vascular endothelium of muscle, myocardium and adipose tissue. The resulting chylomicron remnants are cleared from the circulation by hepatic receptors that recognize apolipoprotein E (apo E). The liver exports triglycerides into the circulation in the core of very-low-density lipoprotein (VLDL) particles. Photo: Paulette Dennis
None
Fig. 2: Mechanism of niacin action. Niacin inhibits the release of free fatty acids from adipose tissue, which leads to decreased VLDL secretion by the liver. FFA = free fatty acids, TG = triglycerides, VLDL = very-low-density lipoprotein, LDL = low-density lipoprotein, HDL = high-density lipoprotein. Photo: Paulette Dennis
Box 1
Box 1
Box 2
Box 2
Box 3
Box 3
See this image and copyright information in PMC

Comment in

  • Managing hypertriglyceridemia.
    MacEachern K. MacEachern K. CMAJ. 2003 Apr 1;168(7):831; author reply 832. CMAJ. 2003. PMID: 12668534 Free PMC article. No abstract available.
  • Managing hypertriglyceridemia.
    Mercola J. Mercola J. CMAJ. 2003 Apr 1;168(7):831-2; author reply 832. CMAJ. 2003. PMID: 12668535 Free PMC article. No abstract available.

References

    1. Lipids. In: Scriver CR, Beaudet AL, Sly WS, Valle D, editors. The metabolic and molecular basis of inherited disease. 8th ed. New York: McGraw-Hill; 2001. p. 2703-988.
    1. Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996;276:882. - PubMed
    1. Austin MA, Hokanson JE, Edwards KL. Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol 1998;81:7B. - PubMed
    1. Dobiasova M, Frohlich J. The plasma parameter log (TG/HDL-C) as an atherogenic index: correlation with lipoprotein particle size and esterification rate in apoB-lipoprotein-depleted plasma (FERHDL). Clin Biochem 2001:34:583-8. - PubMed
    1. Zhao XQ, Morse J, Chait A, Fisher L, Dowdy A, Albers J, et al. Simvistatin plus niacin protect against atherosclerosis progression and clinical events in coronary artery disease patients with metabolic syndrome [abstract 1130-73]. J Am Coll Cardiol 2002;39(5, Suppl A).

Publication types